Reviewer's report
Title:Management of stage II colon cancer-the use of molecular biomarkers for
adjuvant therapy decision
Version: 1Date:23 October 2012
Reviewer: Shuji Ogino
Reviewer's report:
This is an interesting study which examined interactive associations of molecular
markers and treatment on outcome. Molecular classification of CRC is
increasingly important and this is a timely report. After the authors incorporate
points mentioned below, this will be much improved.
Essential revisions (but not minor):
Recently, Yamauchi et al. provided interesting data on colorectal cancer
molecular features (CIMP, MSI, BRAF-mut) (Yamauchi, Morikawa, et al. Gut
2012), and proposed colorectal continuum hypothesis (Yamauchi, Lochhead, et
al. Gut 2012). Please discuss the authors’ own findings, along with these papers.
There may be a possibility of differential response to chemotherapy by tumor
location due to difference in local microenvironment.
CIMP is no longer pos vs. neg. Please discuss CIMP-high vs. CIMP-low vs.
CIMP-neg. With the Weisenberger 5-marker panel (essentially same as Ogino
(5+3) marker panel), CIMP-low has been associated with KRAS mutation (Ogino
et al. J Mol Diagn 2006; Kim et al. Virchows Archiv 2009; Dahlin et al. Clin
Cancer Res 2010). Hinoue et al. (Genome Res 2012) confirmed the existence of
CIMP-low. possbily please provide data (3-5, high; 1-2, low; 0, neg).
Please use only official gene symbols. Check at www.genenames.org
TYMS (not TS) (TS is confusing with "Tumor Suppressor". do not use TS)
TP53 (p53) (p53 can be in parenthesis)
CTNNB1 (b-catenin)
BRAF mutation should be “c.1799T>A (p.V600E)”. The authors analyzed DNA,
and mutations should be described at the DNA level. Follow HGVS guidelines.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Reviewer's report
Title:Management of stage II colon cancer-the use of molecular biomarkers for
adjuvant therapy decision
Version: 1Date:23 October 2012
Reviewer: Shuji Ogino
Reviewer's report:
This is an interesting study which examined interactive associations of molecular
markers and treatment on outcome. Molecular classification of CRC is
increasingly important and this is a timely report. After the authors incorporate
points mentioned below, this will be much improved.
Essential revisions (but not minor):
Recently, Yamauchi et al. provided interesting data on colorectal cancer
molecular features (CIMP, MSI, BRAF-mut) (Yamauchi, Morikawa, et al. Gut
2012), and proposed colorectal continuum hypothesis (Yamauchi, Lochhead, et
al. Gut 2012). Please discuss the authors’ own findings, along with these papers.
There may be a possibility of differential response to chemotherapy by tumor
location due to difference in local microenvironment.
CIMP is no longer pos vs. neg. Please discuss CIMP-high vs. CIMP-low vs.
CIMP-neg. With the Weisenberger 5-marker panel (essentially same as Ogino
(5+3) marker panel), CIMP-low has been associated with KRAS mutation (Ogino
et al. J Mol Diagn 2006; Kim et al. Virchows Archiv 2009; Dahlin et al. Clin
Cancer Res 2010). Hinoue et al. (Genome Res 2012) confirmed the existence of
CIMP-low. possbily please provide data (3-5, high; 1-2, low; 0, neg).
Please use only official gene symbols. Check at www.genenames.org
TYMS (not TS) (TS is confusing with "Tumor Suppressor". do not use TS)
TP53 (p53) (p53 can be in parenthesis)
CTNNB1 (b-catenin)
BRAF mutation should be “c.1799T>A (p.V600E)”. The authors analyzed DNA,
and mutations should be described at the DNA level. Follow HGVS guidelines.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Please review this paper.
user
Reviewer's report
Title:Management of stage II colon cancer-the use of molecular biomarkers for
adjuvant therapy decision
Version: 1Date:23 October 2012
Reviewer: Shuji Ogino
Reviewer's report:
This is an interesting study which examined interactive associations of molecular
markers and treatment on outcome. Molecular classification of CRC is
increasingly important and this is a timely report. After the authors incorporate
points mentioned below, this will be much improved.
Essential revisions (but not minor):
Recently, Yamauchi et al. provided interesting data on colorectal cancer
molecular features (CIMP, MSI, BRAF-mut) (Yamauchi, Morikawa, et al. Gut
2012), and proposed colorectal continuum hypothesis (Yamauchi, Lochhead, et
al. Gut 2012). Please discuss the authors’ own findings, along with these papers.
There may be a possibility of differential response to chemotherapy by tumor
location due to difference in local microenvironment.
CIMP is no longer pos vs. neg. Please discuss CIMP-high vs. CIMP-low vs.
CIMP-neg. With the Weisenberger 5-marker panel (essentially same as Ogino
(5+3) marker panel), CIMP-low has been associated with KRAS mutation (Ogino
et al. J Mol Diagn 2006; Kim et al. Virchows Archiv 2009; Dahlin et al. Clin
Cancer Res 2010). Hinoue et al. (Genome Res 2012) confirmed the existence of
CIMP-low. possbily please provide data (3-5, high; 1-2, low; 0, neg).
Please use only official gene symbols. Check at www.genenames.org
TYMS (not TS) (TS is confusing with "Tumor Suppressor". do not use TS)
TP53 (p53) (p53 can be in parenthesis)
CTNNB1 (b-catenin)
BRAF mutation should be “c.1799T>A (p.V600E)”. The authors analyzed DNA,
and mutations should be described at the DNA level. Follow HGVS guidelines.
Level of interest: An article of outstanding merit and interest in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
assistant